Allen R. Baum

Allen represents life sciences companies in patent and licensing matters. Clients hire Allen to identify and execute strategies to protect key commercial products, license important intellectual assets, and bring lucrative products to market in areas heavily patented by competitors. With an extensive litigation background, he is also frequently retained to evaluate the strength of patents under consideration for licensing, acquisition or investment.

Allen frequently assists clients with strategies for pursuing commercially significant patent portfolios and has managed large portfolios of patent applications for Global Fortune 100 companies. He has also provided opinions on patents protecting products with sales in excess of $1 billion. His representative clients are active in small molecule pharmaceuticals, agricultural products, biotechnology, biochemistry, vaccines, medical devices, ocular medications and implants, green technologies, and advanced materials. 

Allen’s work includes post grant litigation and inter partes review before the U.S. Patent and Trademark Office, freedom-to-operate studies, due diligence review, infringement and validity studies, licensing, Hatch-Waxman litigation, reexamination, and patent preparation and prosecution. 

Active in leadership roles in the IP industry, Allen is a former president of the Licensing Executives Society for the USA and Canada, a former president of the Board of Governor’s for Certified Licensing Professionals (CLP), and was managing partner of his prior firm’s Research Triangle Park office and served on its board of directors for four years. He is also a frequent instructor for intellectual asset management courses and a frequent speaker on life sciences IP topics.

Allen is not regularly admitted to practice in the local courts of Utah.

Allen is not regularly admitted to practice law in the local courts of the District of Columbia. Pursuant to Rule 49 his practice in the District of Columbia is limited to federal courts and agencies.